Novo Nordisk A/S Common Stock (NY:NVO)

37.32 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

99 100 Next >

Why Is Scholar Rock Stock Trading Lower On Monday? ↗

October 13, 2025

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Via Benzinga

Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗

October 13, 2025

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

Via Stocktwits

Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗

October 13, 2025

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

Via The Motley Fool

The Smartest Growth Stock to Buy With $100 Right Now ↗

October 13, 2025

This beaten-down drugmaker is well positioned to turn things around.

Via The Motley Fool

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant ↗

October 07, 2025

Via Stocktwits

Novo Nordisk Retail Traders Stay Bullish Despite Brutal 2025 — Analysts Flag A Key Catalyst That Can Turn Things Around ↗

October 01, 2025

Via Stocktwits

3 Top Healthcare Stocks to Buy in October ↗

October 13, 2025

Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders.

Via The Motley Fool

Topics Economy Government Intellectual Property

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth ↗

October 13, 2025

Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability.

Via Chartmill

Should You Buy Novo Nordisk Right Now? ↗

October 12, 2025

The fallen pharma giant could make a big comeback in 2026.

Via The Motley Fool

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations ↗

October 10, 2025

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

Via Benzinga

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions

October 09, 2025

Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in...

Via MarketMinute

Eastover Opens a Brand New $3.3 Million Novo Nordisk Position ↗

October 09, 2025

Via The Motley Fool

Topics Regulatory Compliance

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion ↗

October 09, 2025

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.

Via Benzinga

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗

October 09, 2025

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Via Investor's Business Daily

Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch ↗

October 09, 2025

Via Stocktwits

Topics Economy Stocks

What’s Driving The Super Rally In Akero Shares On Thursday Morning? ↗

October 09, 2025

Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right.

Via Stocktwits

Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO) ↗

October 08, 2025

Via The Motley Fool

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites ↗

October 07, 2025

Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing weight-loss drug sales.

Via Benzinga

Where Will LLY Be in 5 Years? ↗

October 07, 2025

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.

Via The Motley Fool

Topics World Trade

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss ↗

October 06, 2025

Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results.

Via Benzinga

2 Beaten-Down Stocks Primed for a Comeback ↗

October 05, 2025

The market is sleeping on these stocks, but you don't have to.

Via The Motley Fool

Anthropic’s Claude AI: Seamless Integration into Everyday Life

October 04, 2025

Anthropic, a leading artificial intelligence research company, is making significant strides in embedding its powerful Claude AI into the fabric of daily applications and enterprise workflows. With a...

Via TokenRing AI

Topics Artificial Intelligence

Novo Nordisk (NVO) Soars as HSBC Upgrades to "Buy," Citing Strategic Focus and Pipeline Strength

October 02, 2025

Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC....

Via MarketMinute

Topics Economy

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

October 02, 2025

Via Benzinga

Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors ↗

October 02, 2025

Novo Nordisk (NVO) presents a strong value investment case with an attractive valuation, high profitability, and solid financial health.

Via Chartmill

Why Shares in Novo Nordisk Bumped Higher Today ↗

October 01, 2025

Pfizer's deal with the Trump administration raised hopes that the European company wouldn't be subject to 100% tariffs on certain imported drugs.

Via The Motley Fool

Topics Government World Trade

Q3 2025 Market Marvels: S&P 500's Standout Performers and Their Catalysts

October 01, 2025

As the third quarter of 2025 draws to a close, the financial markets are abuzz with the exceptional performances of several S&P 500 companies. While official data is still being compiled, preliminary...

Via MarketMinute

Topics Artificial Intelligence Data Breach Earnings

Pfizer Plummets as Key Obesity Drug Candidate Faces Major Setback, Shaking Investor Confidence

September 30, 2025

New York, NY – September 30, 2025 – Shares of pharmaceutical giant Pfizer (NYSE: PFE) experienced a dramatic decline today, making it one of the market's bottom performers, following an unexpected and...

Via MarketMinute

Topics Intellectual Property

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.